Effects of serotonin in failing cardiac ventricle: Signalling mechanisms and potential therapeutic implications

Neuropharmacology

Volumn 55, Issue 6, 2008, Pages 1066-1071

  Levy, Finn Olav ^a   Qvigstad, Eirik ^a   Krobert, Kurt A ^a   Skomedal, Tor ^a   Osnes, Jan Bjørn ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

5 HT2A receptor; 5 HT4 receptor; Heart; Heart failure; Inotropic effect; Ventricle

Indexed keywords

CALCIUM ION; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; MESSENGER RNA; MYOSIN LIGHT CHAIN; PIBOSEROD; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN 4 RECEPTOR;

ARTICLE; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; HEART VENTRICLE FAILURE; HUMAN; INOTROPISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR INTRINSIC ACTIVITY; SIGNAL TRANSDUCTION;

ANIMALS; HEART FAILURE; HEART VENTRICLES; HUMANS; MODELS, BIOLOGICAL; MUSCLE, SKELETAL; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGENTS; SIGNAL TRANSDUCTION; SWINE;

EID: 53549095413     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.07.010     Document Type: Article

References (60)

1. Afzal, F., Andressen, K.W., Mørk, H.K., Aronsen, M., Sjaastad, I., Dahl, C.P., Skomedal, T., Levy, F.O., Osnes, J.B., Qvigstad, E. 5-HT4-elicited positive inotropic response is mediated by cAMP and regulated by PDE3 in failing rat and human cardiac ventricles. Br. J. Pharmacol., in press, doi:10.1038/bjp.2008.339.
2. Amsallem E., Kasparian C., Haddour G., Boissel J.P., and Nony P. Phosphodiesterase III inhibitors for heart failure. Cochrane. Database. Syst. Rev. (2005) CD002230
3. 1-AR-induced positive inotropic response in heart is dependent on myosin light chain phosphorylation. Am. J. Physiol. Heart Circ. Physiol. 283 (2002) H1471-H1480
4. 4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. Naunyn-Schmiedeberg's Arch. Pharmacol. 363 (2001) 146-160
5. Beavo J.A., and Brunton L.L. Cyclic nucleotide research-still expanding after half a century. Nat. Rev. Mol. Cell Biol. 3 (2002) 710-718
6. 4 receptor antagonist in heart failure. Br. J. Pharmacol. 150 (2007) 143-152
7. 4 receptors in failing rat ventricular cardiomyocytes. Am. J. Physiol Heart Circ. Physiol. 293 (2007) H2367-H2376
8. 4 receptor cloned from human atrium. FEBS Lett. 412 (1997) 465-474
9. 4 receptor isoforms produced by alternative splicing in the carboxyl terminus. J. Neurochem. 70 (1998) 2252-2261
10. Böhm M., Mittmann C., Schwinger R.H., and Erdmann E. Effects of xamoterol on inotropic and lusitropic properties of the human myocardium and on adenylate cyclase activity. Am. Heart J. 120 (1990) 1381-1392
11. 4(i). Naunyn-Schmiedeberg's Arch. Pharmacol. 369 (2004) 616-628
12. 4 mRNA in heart failure. Naunyn-Schmiedeberg's Arch. Pharmacol. 370 (2004) 157-166
13. 4 receptor-a foetal gene reactivated in heart failure?. J. Mol. Cell. Cardiol. 40 (2006) 944
14. 4 receptors is differentially regulated in hypertrophic and failing rat cardiac ventricle. J. Mol. Cell. Cardiol. 43 (2007) 767-779
15. Chandra M., Gupta V., Johri A.K., Misra R., Kumar A., Gujrati V., and Shanker K. Serotonergic mechanisms in heart failure. Indian Heart J. 46 (1994) 153-156
16. Chien K.R., Knowlton K.U., Zhu H., and Chien S. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J. 5 (1991) 3037-3046
17. 1-adrenoceptors in human atrial myocardium. Naunyn-Schmiedeberg's Arch. Pharmacol. 374 (2006) 249-253
18. 4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. Mol. Pharmacol. 55 (1999) 910-920
19. Cleland J.G. Beta-blockers for heart failure: why, which, when, and where. Med. Clin. North Am. 87 (2003) 339-371
20. Doughty R.N., Whalley G.A., Walsh H.A., Gamble G.D., Lopez-Sendon J., and Sharpe N. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation 109 (2004) 201-206
21. Dvorak A.M. Mast-cell degranulation in human hearts. N. Engl. J. Med. 315 (1986) 969-970
22. Fuder H., Ries P., and Schwarz P. Histamine and serotonin released from the rat perfused heart by compound 48/80 or by allergen challenge influence noradrenaline or acetylcholine exocytotic release. Fundam. Clin. Pharmacol. 8 (1994) 477-490
23. 1-adrenoceptors. Br. J. Pharmacol. 153 (2008) 710-720
24. Hara M., Ono K., Hwang M.W., Iwasaki A., Okada M., Nakatani K., Sasayama S., and Matsumori A. Evidence for a role of mast cells in the evolution to congestive heart failure. J. Exp. Med. 195 (2002) 375-381
25. Hasenfuss G., Blanchard E.M., and Holubarsch C. Influence of alpha- and beta-receptor stimulation on myocardial energetics in rabbit myocardium. Circulation 80 suppl. II (1989) 153
26. Jahnel U., Rupp J., Ertl R., and Nawrath H. Positive inotropic response to 5-HT in human atrial but not in ventricular heart muscle. Naunyn-Schmiedeberg's Arch. Pharmacol. 346 (1992) 482-485
27. 4 receptor and its consequences in early BALB/c mouse embryonic development. BMC. Dev. Biol. 7 (2007) 34
28. 4 receptors mediate arrhythmias?. Trends Pharmacol. Sci. 15 (1994) 451-455
29. s Protein-coupled receptors in human heart. In: Kenakin T., and Angus J.A. (Eds). The Pharmacology of Functional, Biochemical, and Recombinant Receptor Systems (2000), Springer, Berlin Heidelberg New York 73-116
30. Kaumann A.J., and Levy F.O. 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol. Ther. 111 (2006) 674-706
31. 4receptors in the brain and periphery (1998), Springer, Berlin 127-148
32. Kaumann A.J., Sanders L., Brown A.M., Murray K.J., and Brown M.J. A 5-hydroxytryptamine receptor in human atrium. Br. J. Pharmacol. 100 (1990) 879-885
33. Läer S., Remmers F., Scholz H., Stein B., Müller F.U., and Neumann J. Receptor mechanisms involved in the 5-HT-induced inotropic action in the rat isolated atrium. Br. J. Pharmacol. 123 (1998) 1182-1188
34. Lefebvre H., Contesse V., Delarue C., Vaudry H., and Kuhn J.M. Serotonergic regulation of adrenocortical function. Horm. Metab Res. 30 (1998) 398-403
35. Lohse M.J., Engelhardt S., and Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure?. Circ. Res. 93 (2003) 896-906
36. 4 receptors, present in piglet atria and sensitive to SDZ 205-557, are absent in papillary muscle. Eur. J. Pharmacol. 229 (1992) 105-108
37. Mongillo M., McSorley T., Evellin S., Sood A., Lissandron V., Terrin A., Huston E., Hannawacker A., Lohse M.J., Pozzan T., Houslay M.D., and Zaccolo M. Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ. Res. 95 (2004) 67-75
38. Nebigil C.G., Choi D.S., Dierich A., Hickel P., Le Meur M., Messaddeq N., Launay J.M., and Maroteaux L. Serotonin 2B receptor is required for heart development. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 9508-9513
39. 2B receptor in heart leads to abnormal mitochondrial function and cardiac hypertrophy. Circulation 107 (2003) 3223-3229
40. 1-blockade attenuates post-infarct remodelling without improvement in myocardial energy metabolism and function in rats with heart failure. Eur. J. Heart Fail. 5 (2003) 725-732
41. Osnes J.B., Aass H., Andersen G.Ø., and Skomedal T. First-line antihypertensive therapy. Lancet 356 (2000) 509-510
42. Poole-Wilson P.A. ACE inhibitors and ARBs in chronic heart failure: the established, the expected, and the pragmatic. Med. Clin. North Am. 87 (2003) 373-389
43. 4 receptor-mediated inotropic response to serotonin in heart failure. Cardiovasc. Res. 65 (2005) 869-878
44. Qvigstad E., Brattelid T., Sjaastad I., Molenaar P., Birkeland J.A., Andressen K.W., Krobert K.A., Sejersted O.M., Skomedal T., Osnes J.-B., Kaumann A.J., and Levy F.O. Rationale for treatment of heart failure by blockade of ventricular serotonin receptors appearing in heart failure. Proceedings of the 25th European Section Meeting, International Society for Heart Research, Tromsø, Norway, June 21-25, 2005. Medimond International Proceedings, Bologna, Italy (2005) 7-12
45. 4 receptors induced in the acute failing heart. Circ. Res. 97 (2005) 268-276
46. 4 receptor antagonist RS-100302 in experimental atrial flutter and fibrillation. Circulation 100 (1999) 2010-2017
47. Rajagopalan S., and Pitt B. Aldosterone as a target in congestive heart failure. Med. Clin. North Am. 87 (2003) 441-457
48. Rochais F., Abi-Gerges A., Horner K., Lefebvre F., Cooper D.M., Conti M., Fischmeister R., and Vandecasteele G. A specific pattern of phosphodiesterases controls the cAMP signals generated by different Gs-coupled receptors in adult rat ventricular myocytes. Circ. Res. 98 (2006) 1081-1088
49. 2+ movements in anterior aorta and ventricle of Aplysia. J. Neurophysiol. 51 (1984) 361-374
50. 4 receptors in the pig. Naunyn-Schmiedeberg's Arch. Pharmacol. 346 (1992) 629-636
51. Schoemaker R.G., Du X.Y., Bax W.A., and Saxena P.R. 5-Hydroxytryptamine increases contractile force in porcine right atrium but not in left ventricle. Naunyn-Schmiedeberg's Arch. Pharmacol. 346 (1992) 486-489
52. Schoemaker R.G., Du X.Y., Bax W.A., Bos E., and Saxena P.R. 5-Hydroxytryptamine stimulates human isolated atrium but not ventricle. Eur. J. Pharmacol. 230 (1993) 103-105
53. Shah A.M., Andries L.J., Meulemans A.L., and Brutsaert D.L. Endocardium modulates myocardial inotropic response to 5- hydroxytryptamine. Am. J. Physiol. 257 (1989) H1790-H1797
54. Skomedal T., Borthne K., Aass H., Geiran O., and Osnes J.B. Comparison between alpha-1 adrenoceptor-mediated and beta adrenoceptor-mediated inotropic components elicited by norepinephrine in failing human ventricular muscle. J. Pharmacol. Exp. Ther. 280 (1997) 721-729
55. Sole M.J., Shum A., and van Loon G.R. Serotonin metabolism in the normal and failing hamster heart. Circ. Res. 45 (1979) 629-634
56. Tendera M., and Ochala A. Overview of the results of recent beta blocker trials. Curr. Opin. Cardiol. 16 (2001) 180-185
57. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 336 (1990) 1-6
58. Vargas M.L., Hernandez J., and Kaumann A.J. Phosphodiesterase PDE3 blunts the positive inotropic and cyclic AMP enhancing effects of CGP12177 but not of noradrenaline in rat ventricle. Br. J. Pharmacol. 147 (2006) 158-163
59. Vizir V.A., and Berezin A.E. [Relationship between myocardial remodeling and neurohumoral activation in patients with cardiac failure]. Klin. Med. (Mosk). 79 (2001) 21-27
60. 2 adrenoceptor subtype-specific signaling in cardiac myocytes. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 909-914